Loading...
Cell-based immunotherapy, in which autologous T cells are engineered to express receptors targeting cancer-based antigens, is an established treatment for hematologic cancers. Recent studies are expanding these therapies to treat solid tumor malignances.
Investigators from the National Cancer Institute report the case of a patient with pancreatic cancer metastasized to the lungs bearing a KRAS G12D mutation, in which autologous T-cells were engineered to express two allogeneic HLA-restricted KRAS G12D-reactive T-cell receptors. The patient had previously received perioperative FOLFIRINOX, underwent surgical resection of the primary tumor followed by chemoradiotherapy, and developed bilateral lung nodules. She also had received autologous tum…